- Home
- CBRL vs ENGN Comparison
CBRL vs ENGN Comparison
Compare CBRL & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRL | ENGN |
|---|---|---|
| Founded | 1969 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.7M | 647.1M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | CBRL | ENGN |
|---|---|---|
| Price | $28.86 | $7.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $36.89 | $21.08 |
| AVG Volume (30 Days) | ★ 975.9K | 366.4K |
| Earning Date | 06-04-2026 | 06-11-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ 12.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,030,445,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.56 | N/A |
| 52 Week Low | $24.85 | $2.66 |
| 52 Week High | $68.09 | $12.25 |
Technical Indicators
Market Signals| Indicator | CBRL | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 50.24 |
| Support Level | $27.78 | $6.15 |
| Resistance Level | $29.87 | $8.14 |
| Average True Range (ATR) | 1.47 | 0.58 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 30.66 | 39.90 |
Price Performance
Historical ComparisonAbout CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The Cracker Barrel stores consists of a restaurant with a gift shop. The restaurants serve breakfast, lunch and dinner. The gift shop offers a variety of decorative and functional items specializing in rocking chairs, holiday gifts, toys, apparel and foods.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.